News Center

The latest news, insights and resources from Prothena

RDCC in Washington, D.C. during Rare Disease Week

April 11, 2023/by Moises Zanetti

Share this story

Share on Facebook
Share on X
Share on LinkedIn
Share by Mail

/wp-content/uploads/2019/12/prothena_logo.svg 0 0 Moises Zanetti /wp-content/uploads/2019/12/prothena_logo.svg Moises Zanetti2023-04-11 11:47:522023-04-11 11:50:02RDCC in Washington, D.C. during Rare Disease Week

Scroll to top

US Healthcare Professional Confirmation

The purpose of this resource is to provide information to US healthcare professionals (HCPs) about Prothena’s investigational drug candidates.

This resource contains medical and scientific information related to Prothena’s products and/or uses that have not been approved by any regulatory authority (e.g., FDA, EMA).

If you are a patient or caregiver, please discuss any medical or treatment questions with your healthcare provider.

All Prothena drugs (wholly-owned or partnered) referenced herein are investigational drugs and not approved by any regulatory authority.